To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma

NCT06742138 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

284

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: QL2109
DRUG: Pomalidomide
DRUG: Dexamethasone
DRUG: DARZALEX FASPRO®

Sponsor

Qilu Pharmaceutical Co., Ltd.